Packaging
20×15 Blister
Dolcuris-IB Tablets by Biocuris is a powerful dual-action oral formulation combining two trusted therapeutic agents: Ibuprofen IP (Non-Steroidal Anti-Inflammatory Drug – NSAID) and Paracetamol IP (Analgesic and Antipyretic). Engineered for fast and sustained relief, this combination is widely prescribed to manage mild-to-moderate pain, reduce inflammation, and effectively bring down fever.
By working simultaneously via different pathways in the body, Dolcuris-IB delivers enhanced efficacy compared to single-ingredient pain relievers, making it an essential product for retail pharmacy shelves, clinical prescriptions, and hospital supply chains. Manufactured under strict quality control standards, it offers a high safety profile and dependable therapeutic results.
Dual-Action Relief: Combines an anti-inflammatory (Ibuprofen) with an effective pain and fever reducer (Paracetamol).
Rapid Action: Quick absorption ensures swift relief from acute pain conditions and high body temperature.
Versatile Management: Highly effective for headaches, toothaches, muscle pain, backaches, and joint discomfort.
Reduces Inflammation: Actively targets and decreases swelling and inflammation at the source.
Q1: What is Dolcuris-IB used for?
A: It is used to relieve mild-to-moderate pain from headaches, dental pain, body aches, and joint swelling, while also rapidly reducing fever.
Q2: How does the combination of Ibuprofen and Paracetamol work?
A: Ibuprofen reduces pain and inflammation at the site, while Paracetamol blocks pain signals in the central nervous system and regulates body temperature.
Q3: Can I take this tablet on an empty stomach?
A: It is highly recommended to take Dolcuris-IB with food or milk to minimize the risk of mild stomach irritation or gastric discomfort.
Q4: Is Dolcuris-IB available for PCD Pharma Franchise partnerships?
A: Yes, Biocuris offers lucrative PCD Pharma Franchise and third-party contract manufacturing options for this high-demand formulation across India.
Reviews
There are no reviews yet.